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Abstract
Background: The clinical outcomes associated with Chagas disease remain poorly understood. In addition to the
burden of morbidity, the burden of mortality due to Trypanosoma cruzi infection can be substantial, yet its
quantification has eluded rigorous scrutiny. This is partly due to considerable heterogeneity between studies, which
can influence the resulting estimates. There is a pressing need for accurate estimates of mortality due to Chagas
disease that can be used to improve mathematical modelling, burden of disease evaluations, and cost-effectiveness
studies.
Methods: A systematic literature review was conducted to select observational studies comparing mortality in
populations with and without a diagnosis of Chagas disease using the PubMed, MEDLINE, EMBASE, Web of Science
and LILACS databases, without restrictions on language or date of publication. The primary outcome of interest was
mortality (as all-cause mortality, sudden cardiac death, heart transplant or cardiovascular deaths). Data were
analysed using a random-effects model to obtain the relative risk (RR) of mortality, the attributable risk percent
(ARP), and the annual mortality rates (AMR). The statistic I2 (proportion of variance in the meta-analysis due to study
heterogeneity) was calculated. Sensitivity analyses and publication bias test were also conducted.
Results: Twenty five studies were selected for quantitative analysis, providing data on 10,638 patients, 53,346
patient-years of follow-up, and 2739 events. Pooled estimates revealed that Chagas disease patients have
significantly higher AMR compared with non-Chagas disease patients (0.18 versus 0.10; RR = 1.74, 95 % CI 1.49–2.03).
Substantial heterogeneity was found among studies (I2 = 67.3 %). The ARP above background mortality was 42.5 %.
Through a sub-analysis patients were classified by clinical group (severe, moderate, asymptomatic). While RR did not
differ significantly between clinical groups, important differences in AMR were found: AMR = 0.43 in Chagas vs. 0.29
in non-Chagas patients (RR = 1.40, 95 % CI 1.21–1.62) in the severe group; AMR = 0.16 (Chagas) vs. 0.08 (non-
Chagas) (RR = 2.10, 95 % CI 1.52-2.91) in the moderate group, and AMR = 0.02 vs. 0.01 (RR = 1.42, 95 % CI 1.14–1.77)
in the asymptomatic group. Meta-regression showed no evidence of study-level covariates on the effect size.
Publication bias was not statistically significant (Egger's test p=0.08).
Conclusions: The results indicate a statistically significant excess of mortality due to Chagas disease that is shared
among both symptomatic and asymptomatic populations.
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Background
Chagas disease is a neglected tropical disease (NTD) of
global health concern with around 13 % of the population
residing in Latin America considered at risk of Trypano-
soma cruzi (Kinetoplastida: Trypanosomatidae) infection.
The infection is endemic in 21 countries [1]. Currently, it
is estimated that Chagas disease affects between 6 and 8
million individuals, with an attributed number of deaths
of approximately 12,000 per year worldwide [2].
Although Chagas disease was first described more than
a century ago, the course of the disease and its clinical
outcomes are still not well understood [3]. The clinical
course of Chagas disease is usually divided into acute and
chronic phases. In most cases, the initial infection is
asymptomatic. However, a few cases will present acute
symptoms and in some instances death may occur [4, 5].
Infected individuals surviving the acute phase―which is
the most common occurrence―enter the indeterminate
stage, characterised by a long asymptomatic period before
the onset of clinical signs and symptoms. The latter can
last 10–30 years or until the end of an individual’s life [6].
Based on early cohort studies, an estimated 20-30 % of in-
fected individuals would eventually develop heart disease,
with an associated increased mortality [5, 7, 8]. A recent
cohort study on infected blood donors in Brazil showed
an annual rate of progression to cardiomyopathy of 1.85 %
per year [9] and other studies have found that Chagas dis-
ease is an independent risk factor for stroke [10, 11]. Al-
though Chagas disease is one of the NTDs globally with a
large proportional contribution of years of life lost (YLL)
to its total disability-adjusted life years (DALYs) [12], there
is a paucity of research measuring rigorously disease pro-
gression rates according to the different stages described
above and quantifying excess mortality due to Chagas dis-
ease compared with mortality rates in non-chagasic
individuals.
Processes of extensive inflammation and fibrosis appear
to be involved in the physiopathology of the chagasic car-
diomyopathy [7]. The clinical manifestations of Chagas
disease may be characterised by the grade of myocardial
damage [13]. However, although some similarities in clin-
ical presentation occur, there is evidence that Chagas
cardiomyopathy has specific characteristics that could in-
fluence mortality when compared with other aetiologies
or with idiopathic dilated cardiomyopathy [14].
A better understanding of the magnitude of morbidity
and mortality associated with Chagas disease is impera-
tive for appropriately measuring burden of disease and
evaluating the cost effectiveness of strategies to prevent
and control T. cruzi infection and its clinical sequelae.
This is because mathematical modelling of infection and
disease, ensuing burden of disease quantifications, and
accompanying cost-effectiveness studies critically rely
on estimates of Chagas disease-related morbidity and
mortality rates [2, 15, 16]. However, inspection of the
literature reveals a great deal of variation in the re-
ported mortality rates attributed to Chagas disease,
raising difficulties of interpretation and hampering their
use in model parameterisation.
In 2007, Rassi et al. [17] reviewed predictors of mortal-
ity in chronic Chagas disease, reporting annual mortality
rates from a selection of papers, which ranged from 0.2
to 19.2 % per year without a control group comparison.
More recently, and specifically for sudden death, De
Souza et al. [18] found, in a retrospective cohort study,
that mortality rates varied according to the clinical
severity of the chronic phase, being estimated as 1.5 %,
25 %, and 51 %, for mild, moderate and severe cases, re-
spectively (see also Rassi et al. [19]). The inconsistency of
reported rates is likely to be the result of heterogeneity in
the clinical presentation of the populations studied. Add-
itionally, Linetzky et al. [20].conducted a systematic review
comparing cardiovascular outcomes between Chagas and
non-Chagas patients, and reported higher mortality risk in
chagasic patients but without quantifying the effect.
In view of the above, the objectives of the present
study are: 1) to conduct a systematic review of the litera-
ture in order to identify those studies in which mortality
was measured for both chagasic and non-chagasic (con-
trol) patients, 2) to perform a meta-analysis of such
studies in order to derive estimates of risk ratios, attrib-
utable risk, and mortality rates associated with Chagas
disease, and 3) to provide overall and stage-specific esti-
mates of mortality for further mathematical modelling of
the relationship between infection and morbi-mortality,
burden of disease estimation and economic evaluations.
Methods
The PRISMA (Preferred Reporting Items for Systematic
Reviews and Meta-Analyses) guidelines and checklist
was used to ensure inclusion of relevant information in
the analysis [21] (Additional file 1).
Search strategies
Searches were conducted in PubMed (online version of
Index Medicus, produced by the USA National Library
of Medicine, NLM); MEDLINE (a subset of PubMed
(~98 %) made available by NLM); EMBASE (Excerpta
Medica dataBASE), Web of Science (Core Collection)
and LILACS (Latin American and Caribbean Health data-
base), without time filters until the 31st of September
2015. The search algorithm combined four search terms
to represent the grouping of the concepts most relevant to
the question under scrutiny: 1) Chagas disease, 2) mor-
tality, 3) progression, and 4) survival analysis. This
search algorithm was applied to each database to main-
tain consistency in the results generated. The full
search terms for individual databases are available in
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Additional file 2: Table S1. All the titles and abstracts
were assessed by two independent investigators (ZMC
and OO), eliminating studies that did not meet the in-
clusion criteria: i. cohort studies, ii) comparing Chagas
and non-Chagas patients, iii) with follow-up for more
than one year. Disagreements were resolved by consen-
sus, and in the case of persistent disagreement, the full
text of the article was examined. References cited in the
selected papers were inspected and if appropriate
included as secondary searches.
Data extraction
Each paper that was selected for analysis of the full text
was reviewed carefully and the relevant information was
extracted. In some instances information was extracted
from available data tables or figures, where values were
not explicitly mentioned in the text. A data extraction
table was designed to obtain information from each eli-
gible study. The following items were included: first
author; year of publication; year of study; location of the
study; study design; sample size; proportion of men in
the study population; age group; mean/median age of
study participants; number of deaths; years of follow up;
number of persons-year of follow up; loss to follow up
(drop-out rate); clinical classification (severe, moderate,
asymptomatic); reported effect size and corresponding
adjustments.
In order to obtain results accounting for severity of
symptoms, the data were extracted and classified accord-
ing to the clinical severity reported in each study, as
follows:
– Severe stage: this stage included patients with
cardiac complications, attending health facilities and
usually classified according to the New York Heart
Association Functional Classification (NYHA) III
and IV. Also one study [22] which included only a
population under resynchronization therapy was
considered in this stage.
– Moderate stage: this included populations mostly
classified according to NYHA I and II criteria.
– Asymptomatic/general population: this category
included both asymptomatic populations―mainly
from population studies―and also individuals with
minimal electrocardiogram (ECG) damage or
without report of deleterious ejection fraction.
– All stages: this category included studies in which
several clinical stages were used in comparison to
clinically similar but uninfected controls.
Quality assessment
The Newcastle-Ottawa Scale (NOS) was used to assess
the risk of bias of the studies included in this review in a
standardised manner, as this metric is easy to interpret
and is recommended for quality assessment by the
Cochrane Collaboration [23]. The NOS scale assesses
each study on three components, namely, the selection
of the study population, a valuation of comparability of
the study groups, and an assessment of the outcome of
interest. Each study is scored for each component by the
award of “stars”. The checklist, amendments made to
the original scale and details on the assessment for each
study are presented in Additional file 2: Table S2. The
critical appraisal of the studies was conducted following
the data extraction process. Three levels of quality were
considered: low, moderate and high. Due to the small
number of studies identified, studies were not excluded
based on quality assessment. Nevertheless, a separate
analysis was done only using papers deemed as of “high
quality”.
Statistical analysis
Studies were required to report hazard ratios (HRs),
relative risk ratios (RRs), odds ratios (ORs) and their
95 % confidence intervals (CIs) or to provide adequate
data to allow the 95 % CI to be calculated. Because not
all studies reported deaths in a uniform manner, the ana-
lysis is based on all-cause mortality, cardiac death, heart
transplant or death due to stroke. For quantitative ana-
lysis, studies were included if enough information was
provided to estimate crude RRs.
Selected studies differed substantially in terms of sample
size, study location and clinical characteristics; therefore,
heterogeneity in mortality rates was potentially important.
Thus, a random-effects model was used to test differences
in rates of mortality between chagasic and non-chagasic
populations. For the random-effects model, tau-squared
(τ2) was presented as a measure of the between-study vari-
ance. For comparison, results using a fixed-effects model
are also presented (Additional file 2: Figure S1).
Heterogeneity among studies was measured using
Cochran's Q test and I2 statistic. Cochran's Q is computed
by summing the squared deviations of each study’s estimate
from the overall estimate, weighting each study’s contribu-
tion. The p-values for this test are obtained by comparing
the Q statistic to a chi square distribution with k–1 degrees
of freedom (df) (where k is the number of studies). The I2
statistic measures the degree of inconsistency in the studies’
results. Formally, I2 = 100 % × (Q–df)/Q, measuring the
percentage of variation across studies that is due to hetero-
geneity rather than to chance [24].
To explore further the source of potential heterogeneity
in mortality between studies, we used meta-regression
techniques to formally identify potential covariates of the
estimated effect on mortality rates [25, 26]. Covariates
tested included clinical characteristics (as defined above),
starting year of the study, sex (as proportion of males),
and location of study (country).
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We explored publication bias by drawing funnel plots,
enabling quantification of bias using Egger’s regression
asymmetry test [27]. Interpretation of funnel plots is fa-
cilitated by inclusion of diagonal lines representing the
95 % confidence limits around the summary effect. In
the absence of heterogeneity, 95 % of the studies should
lie within the funnel defined by these lines (because these
are not strictly speaking 95 % limits, they are referred to
as “pseudo 95 % confidence limits”) [28]. A trim-and-fill
technique (aimed both at identifying and correcting funnel
plot asymmetry) was then used to re-estimate excess mor-
tality correcting for publication bias (i.e., by incorporating
the hypothetically missing studies) [29].
Finally, sensitivity analyses were also performed by 1)
sequentially removing one study at a time and re-
evaluating the model to explore the impact of potential
outliers on estimates of excess mortality, and 2) restrict-
ing the analysis to ‘high quality’ papers.
The crude mortality rates were calculated for each clin-
ical group and RR values were used for meta-analysis.
Annual mortality rates (AMR) are reported (unless other-
wise stated) per person per year. The Attributable Risk
Percent (ARP) was used to estimate excess mortality above
background mortality rate, as (RR − 1)/RR expressed in
percent.
All analyses were performed using Stata 13.1 (StataCorp,
College Station, TX).
Results
Description of included studies and data obtained
The systematic literature search (Fig. 1), yielded 6523 dis-
tinct publications, which were identified and reviewed.
After exclusions, 31 entries were selected for inclusion
for qualitative analysis. Twenty seven out of the 31
studies were conducted in Brazil; the remaining four
were conducted in Bolivia, Chile, United States of
America, and Venezuela, each country contributing one
study. A total of six studies were excluded from quanti-
tative analysis due to these reports either not providing
enough information in the paper [30–32], the outcome
was not clearly measured as part of the study [33, 34]
or due to the absence of deaths during the follow-up
period [35]. A total of 25 were selected for quantitative
meta-analysis, of which 12 (48 %) were classified as of
high quality, 11 (44 %) as of moderate quality, and 2
(8 %) as of low quality. Detailed results on quality as-
sessment of the 25 studies are presented in Additional
file 2: Table S2. These studies yielded data on 10,638
patients, 53,346 patient-years of follow-up, and 2739
events.
Only 17 out of the selected 25 studies provided actual
metrics for the relationship between Chagas disease and
death, all of them reporting a positive effect (RR, HR or
OR greater than 1). Only 9 of these studies adjusted for
covariates such as age, sex, other risk factors, schooling,
Fig. 1 Flow diagram describing the selection of studies included in the meta-analysis
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etc. The complete list of studies included in the quanti-
tative analysis is provided in Table 1.
Pooled estimates
When pooling all studies, the overall RR was 1.74 (95 %
CI 1.49–2.03. This RR reflects the overall excess mortal-
ity for chagasic patients compared with similar controls
regardless of their clinical presentation. The correspond-
ing overall annual mortality rate (AMR) was 0.18 among
the chagasic groups versus 0.10 among the control
groups. The observed I2 statistic showed substantial het-
erogeneity among studies (I2 = 67.3 %, τ2 = 0.07, p < 0.01)
(Fig. 2). Results were similar for a fixed-effects model
(Additional file 2: Figure S1) confirming the robustness of
our conclusions. The value of ARP above the overall back-
ground mortality rate was estimated to be 42.5 %.
Exploring heterogeneity
The contribution of study heterogeneity varied between
clinical groups, with the greatest heterogeneity being ex-
hibited in the clinical presentation category that included
all stages (I2 = 83 %, p < 0.01). The heterogeneity present
in the moderate and severe category was lower and not
statistically significant (I2 = 47.1 %, p = 0.07 and I2 =
42.8 %, p = 0.12 respectively). The lowest degree of het-
erogeneity was present among the asymptomatic cases
(14.7 %, p = 0.32). Figure 2 and Additional file 2: Table
S3 present detailed results.
While there was clear evidence of differences in
terms of AMRs between disease groups, the magnitude
of excess mortality among chagasic patients, measured
by the RRs, did not differ significantly between clinical
groups. For the severe clinical group, AMR was 0.43 in
the patients with Chagas versus 0.29 in the non-
Chagas patients (RR = 1.40, 95 % CI 1.21–1.62). For
the moderate clinical group the corresponding AMR
values were 0.16 versus 0.08 (RR = 2.10, 95 % CI 1.52–
2.91) and for the asymptomatic/general population cat-
egory AMR was 0.02 (in Chagas disease patients) versus
0.01 in non-(RR = 1.42, 95 % CI 1.14–1.77).
Meta-regression on other covariates showed no evi-
dence of significant confounding factors when adjusting
for clinical classification, starting year of the study, pro-
portion of males included, and location (country) of the
study. However, sufficient information to conduct the
meta-regression analysis was only available in 19 out of 25
selected studies. These results are summarised in Add-
itional file 2: Table S4. No further investigation of the im-
pact of sub-groups was feasible due to the small number
of studies available.
Publication bias analysis and sensitivity analysis
Publication bias was explored firstly by looking at fun-
nel plots (Fig. 3). The relative lack of symmetry among
small-sample studies indicated a potential bias, consist-
ent with small studies failing to report negative results.
Although this bias was not significant using the Egger’s
test (p = 0.08), we used trim-and-fill methodology (Add-
itional file 2: Figures S2 and S3) to correct for this po-
tential bias, re-estimating the overall excess mortality.
Initial estimates were robust to publication bias, and
after correction the overall RR decreased only slightly to
1.42 95 % CI 1.19–1.70.
In the sensitivity analysis, the point and uncertainty
estimates of the RR remained unaffected by removing
in turn a single study (Additional file 2: Figure S4),
leading to the conclusion that no outliers were
present in our study selection. Finally, using only the
“high quality” papers yielded a RR = 2.07 (95 % CI
1.54–2.78), emphasizing the robustness of our results
and suggesting a low impact of the quality of studies
on the estimated excess mortality values (Additional
file 2: Figure S5).
Discussion
Our study is the first to review, collate and analyse avail-
able (published) studies on mortality rates associated
with Chagas disease using a robust and coherent meta-
analytical framework. One of the motivations for this
meta-analysis was to assess whether Chagas disease in-
duces a higher risk of mortality compared to control
populations with similar clinical symptoms. The overall
excess mortality, estimated as a relative risk ratio, was
equal to 1.74 (95 % CI 1.49–2.03), which was robust to
both publication bias (RR = 1.42, 95 % CI 1.19–1.70) and
highest quality studies (RR = 2.07, 95 % CI 1.54–2.78).
Interestingly, this (statistically significant) magnitude
of excess mortality appeared to affect equally patients
with mild, moderate or severe symptoms (relative to
their baseline, background mortality). By contrast, AMRs
increased with clinical severity, from 0.02 in asymptom-
atics to 0.43 in those with severe symptoms (in Chagas
patients), whereas AMR values ranged from 0.01 in
asymptomatics to 0.29 in those with severe disease but
without Chagas disease.
We found no significant impact of sex and study loca-
tion (country) on excess mortality. However, larger stud-
ies that have focused only on cohorts of chagasic
patients, consistently report men as being at increased
risk of cardiac disease and death [9, 36]. Country of
study may reflect a differential distribution of T. cruzi
genotypes, and these are believed to influence disease
progression and hence mortality [37]. The fact that no
effect of country was found in our study may be due to
the relatively limited number of studies with informative
data available and their small sample sizes. It may also
be possible that although disease progression rates may
indeed be influenced by country (proxy for T. cruzi
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Table 1 Characteristics of the 25 studies included in the meta-analysis of Chagas disease-associated mortality
First
author,
year [Ref]
Country Outcome Study
period
Diagnostic
test
Population type Control group Mode of
death
Disease
classification
Sample
size
Outcome Person-
yrs of
follow
up
Crude
RR
Reported effect estimate
exp/
non-
exp
exp/non-
exp
exp/
non-
exp
Estimate
(95% CI)
Adjusted by
variables
Coura,
1985 [51]
Brazil Death 1974-
1984
Serology General population
endemic area
(included
undetermined and
cardio-myopathy)
Same population but
uninfected
Cardio-
myopathy
All stages 235/216 54/23 2350/
2160
2.16 2 times
higher
(NR)
NR
Pereira,
1985 [52]
Brazil Death 1976-
1980
IFAT & CF General population -
Municipality La Lapa
General population -
same municipality
SD (64.7%) Asymptomatic/
GenP
192/188 22/6 1152/
1128
3.59 NR(NR) NR
Maguire,
1987 [53]
Brazil Death 1974-
1980
IFAT & CF
& ELISA
Asymptomatic from
rural Brazilian
community. Normal
ECG
Asymptomatic from
rural Brazilian
community. Normal
ECG
NR Asymptomatic/
GenP
40/116 3/3 949/
771
0.81 RR=1.8
(0.8–4.2)
NR
Mota, 1990
[54]
Brazil Death 1974-
1983
IFAT & CF
& ELISA
Rural population Rural population,
slightly healthier
NR Asymptomatic/
GenP
488/509 34/28 3842/
3663
1.16 RR=1.1
(NR)
Age adjusted
Bestetti &
Muccillo,
1997 [8]
Brazil Cardiac
death
1990-
1993
NR Left ventricular
dilatation in ECG.
Cardiomegaly in the
chest X-ray. With or
without symptoms
Similar, uninfected.
HTA 34%
SD (38%) Moderate
stage
75/50 21/3 225/
150
4.67 OR=6.1
(1.7–
21.7)
Not adjusted
Pimenta &
Valente,
1999 [55]
Brazil Cardiac
death
1977
1996
CF & IFAT
& HAI
Asymptomatic
individuals with
bundle branch block
(RBBB = 98.2%)
Sclerosis of the
conducting system of
the heart (Lev-
Lenègre’s disease)
(RBBB: 48.3%)
SD (50%) Asymptomatic/
GenP
55/29 17/3 554/
229
2.34 NR (NR) NR
Freitas,
2005 [56]
Brazil Death 1991-
2000
Serology NYHA III or IV IDC NR Severe stage 242/454 110/156 516/
968
1.32 HR=1.63
(1.10–
1.43)
NR
Oliveira,
2005 [57]
Brazil Death 1993-
1995
NR Systolic ventricular
dysfunction (LVEF
<55%) at the day of
hospitalisation.
Chagas in 44% of
patients
Any aetiology
identified
NR Severe stage 56/70 50/51 71/89 1.23 RR=2.66
(1.10–
6.46)
Not adjusted
De
Campos
Lopes,
2006 [49]
Brazil Cardiac
death
1998-
2000
NR Severe HF;
hospitalized
subsequent-ly. HT
was considered a
censored event
Hospitalized from the
same clinic
NR Severe stage 102/392 72/169 204/
784
1.64 NR (NR) Age and
controlled for
relevant
covariates:
health system,
myocardial
infarction, HTA
C
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Table 1 Characteristics of the 25 studies included in the meta-analysis of Chagas disease-associated mortality (Continued)
Heringer-
Walther,
2006 [58]
Brazil Cardiac
death or
HT
2001-
2006
2 positive
serologies
Dilated cardio-
myopathy. All stages
Idiopathic dilated
cardio-myopathy.
Other structural
cardiac diseases and
comor-bidities were
excluded in both
groups
NR All stages 274/504 8/10 716/
1108
1.24 OR=3.34
(1.90–
5.89)
NR
Braga,
2008 [59]
Brazil Death 2003-
2004
NR HF and moderate to
severe left ventricle
systolic dysfunction
Other aetiologies not
specified
NR Moderate
stage
89/102 16/10 89/102 1.83 OR=1.67
(0.67–
4.41)
Education level
Silva, 2008
[60]
Brazil Death NR NR Admitted for
decom-pensated HF.
NYHA III-IIV
Other aetiologies NR Severe stage 122/232 84/111 122/
232
1.44 NR (NR) NR
Lima-Costa
2010a [61]
Brazil Death 1997-
2007
HAI & 2
ELISA tests
Bambui, general >60
years age
General population >
60 years age
NR Asymptomatic/
GenP
524/874 257/310 4569/
7621
1.38 NR,
p<0.01
Age, sex, and a
number of risk
factors
Lima-
Costa,
2010b [50]
Brazil Stroke 1997-
2007
HAI & 2
ELISA tests
Bambui, general
population >60
years age (RBBB in
23.5%, in schooled =
20%)
General population >
60 years of age and
significantly healthier
than chagasic patients
(RBBB in 3.3%) and
schooled (50%)
Stroke Asymptomatic/
GenP
563/915 20/25 3479/
6261
1.40 HR=1.56
(1.32–
1.85)
Age, sex,
schooling,
other risk
factors and C-
reactive protein
level
Nunes,
2010 [62]
Brazil Cardiac
death or
HT
1999-
2008
NR HF, dilated cardio-
myopathy
(diameter/ body
surface area ≥31
mm) and LVEF
<55%. NYHA III/IV in
25%
Same criteria but
Idiopathic dilated
cardio-myopathy
(NYHA III/IV 27%)
Progressive
HF (48%).
SD (42%)
Moderate
stage
224/63 91/22 737/
207
1.16 HR=2.35
(1.25–
4.44)
NR
Issa, 2010
[40]
Brazil Death or
HT
1999-
2000
IFAT & HAI
& ELISA
Clinical trial.
Irreversible chronic
HF of at least 6-
month duration
Other aetiologies, not
specified
NR All stages 68/388 49/180 250/
1428
1.55 NR (NR) Cox
proportional
hazards
regression
model
Cardoso,
2010 [63]
Brazil Death 2006-
2007
ELISA &
IFAT
NYHA IV, admitted;
poor perfusion and
congestion. (LVEF) <
45.0%
HTA, Idiopathic,
vasculopathic; alcohol
cardiomyopathy
Progressive
HF
Severe stage 33/67 22/24 68/139 1.87 HR=2.48
(1.28–
4.78)
Multi-variate
analysis
Conceição-
Souza,
2010 [64]
Brazil Death 2008-
2010
NR (LVEF) < 45.0%.
Onset of
symptoms>1 month
Same criteria and
excluded co-
morbidities
NR Moderate
stage
100/62 6/2 100/62 1.86 NR (NR) NR
Cruz, 2010
[65]
Brazil Cardiac
death
NR NR HF; clinics, patients
under maximal
tolerated medical
treatment
IDC (33%), HTA (13%),
ischemic (12%)
SD and
progressive
HF
Moderate
stage
21/55 7/11 23/61 1.69 RR=2.75
(1.35–
5.63)
NR
Brazil Serology NR 246/106 109/16 2.932
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Table 1 Characteristics of the 25 studies included in the meta-analysis of Chagas disease-associated mortality (Continued)
Barbosa,
2011 [66]
Death or
HT
2000-
2008
LVEF <55% in ECG
or <50% on Radio-
nuclide
ventriculography
IDC with same ECG
criteria and in the
absence of
concomitant
obstructive coronary
artery disease
Moderate
stage
574/
247
HR=3.29
(1.89–
5.73)
Cox
proportional
hazards model
multi-variate
analysis
Ayub-
Ferreira,
2013 [39]
Brazil Death 1999-
2010
ELISA &
IFAT & HAI
Clinical trial. Chagas
All stages
Similar but uninfected.
Mixed aetiology, not
specified
SD (14.5%),
HF (22.2%)
All stages 55/287 31/29 196/
1024
5.58 HR= 2.76
(1.34–
5.6)
NR
Bestetti,
2013 [67]
Brazil Death 2000-
2008
Serology Chronic systolic HF Same criteria for
systemic HTA and
chronic systolic heart
failure
NR Moderate
stage
244/130 185/35 1220/
650
2.82 HR=2.2
(1.47–
3.40)
Cox
proportional
hazard model
adjusted for
confounders
Peixoto,
2015 [22]
Brazil Death 2005-
2012
NR Patients under
cardiac
resynchronization
therapy; mean LVEF
= 25.3
Same characteristics
but Ischemic and
idiopathic aetiologies
NR Severe stage 115/311 86/111 310/
839
2.10 NR (NR) NR
Traina,
2015 [68]
USA
and
CAa
Death or
HT
2007-
2010
IFAT &
ELISA
Cardio-myopathy
with left ventricular
ejection fraction
(LVEF of ≤40%) and
previous residence
in Latin America
Any aetiology
identified
NR Moderate
stage
25/110 9/11 42/209 4.07 HR=4.46
(1.8–
10.8)
Un-adjusted
Sherbuk,
2015 [69]
Bolivia Death 2012-
2013
ELISA &
HAI &
TESA blot
From asymptomatic
to severe cases
Similar stages but
uninfected
NR All stages 160/60 23/4 394/
462
2.42 HR=1.78
(1.19–
2.65)
NR
ID identification; exp exposed (Chagas-positive); non-exp non-exposed (Chagas-negative); Crude RR crude relative risk estimated manually form the data in the paper; 95%CI 95% Confidence Interval; HR hazard ratio; OR
odds ratio; CF complement fixation test; ELISA Enzyme-Linked Immunosorbent Assay; HAI hemagglutination inhibition test; IFAT immunofluorescent test; TESA Trypanosoma cruzi excreted-secreted antigens blot; LVEF
left ventricular ejection fraction; ECG electrocardiogram; RBBB right bundle branch block; IDC idiopathic dilated cardiomyopathy; HF heart failure; HT heart transplant; HTA arterial hypertension; SD sudden death; GenP
general population; NYHA New York Heart Association Functional Classification; NR not reported. aCA Central America 90%. The references are as appear on the main text
C
ucunubá
et
al.Parasites
&
Vectors
 (2016) 9:42 
Page
8
of
13
genotypes), excess mortality is not, once a given clinical/
symptomatic stage has been reached.
Some researchers have suggested that the poorer prog-
nosis in chagasic patients compared to that in patients
with other aetiologies, under a similar ventricular func-
tion, may be driven by the occurrence of malignant ven-
tricular arrhythmias and consequently sudden death
[38]. However, there is strong evidence suggesting that
progressive heart failure has become more important
than sudden death as the most common mode of death
in Chagas disease, mainly as a consequence of the
introduction of better anti-arrhythmic therapy, such as
beta-blockers and devices [39]. Some studies suggest
that the introduction of beta-blocker agents has attenu-
ated the poor outcome of chagasic patients, making it
similar to that of patients with other cardiac aetiologies
[40]. We conjectured that this gradual therapeutic im-
provement could have influenced temporal trends of mor-
tality in the two groups under comparison (Chagas and
non-Chagas disease patients) [39, 41]. We tested this hy-
pothesis by exploring whether the effect size estimated
changed according to the starting year of the study―a
NOTE: Weights are from random effects analysis
.
.
.
.
Overall  (I-squared = 67.3%, p = 0.000)
Cardoso, 2010 [63]
Braga, 2008 [59]
Pimenta & Valente, 1999  [55]
Nunes, 2010 [62]
Barbosa, 2011 [66]
Freitas, 2005 [56]
Subtotal  (I-squared = 42.8%, p = 0.120)
Heringer-Walther,2006 [58]
ID
Peixoto, 2015 [22]
Maguire, 1987 [53]
Bestetti, 2013  [67]
All Stages
Subtotal  (I-squared = 83.0%, p = 0.000)
Severe Stage
Oliveira, 2005 [57]
Coura, 1985 [51]
Traina, 2015 [68]
Bestetti & Muccillo, 1997 [8]
De Campos-Lopes, 2006 [49]
Conceição-Souza, 2010 [64]
Subtotal  (I-squared = 14.7%, p = 0.320)
Lima-Costa, 2010b [50]
Issa, 2010 [40]
Silva, 2008 [60]
Mota, 1990 [54]
Cruz, 2010 [65]
Pereira, 1985 [52]
Asymptomatic/General population
Lima-Costa, 2010a [61]
Sherbuk, 2015 [69]
Ayub-Ferreira, 2013  [39]
Moderate Stage
Study
Subtotal  (I-squared = 47.1%, p = 0.066)
1.74 (1.49, 2.03)
1.66 (0.99, 2.79)
1.71 (0.81, 3.59)
2.30 (0.68, 7.78)
1.14 (0.74, 1.78)
2.62 (1.58, 4.35)
1.27 (1.01, 1.58)
1.40 (1.21, 1.62)
1.24 (0.49, 3.12)
RR (95% CI)
1.86 (1.44, 2.40)
0.81 (0.16, 4.02)
2.58 (1.82, 3.66)
2.52 (1.39, 4.58)
1.13 (0.84, 1.54)
2.13 (1.31, 3.46)
3.53 (1.54, 8.07)
4.35 (1.32, 14.35)
1.47 (1.16, 1.87)
1.81 (0.38, 8.71)
1.42 (1.14, 1.77)
1.44 (0.80, 2.58)
1.46 (1.09, 1.96)
1.26 (1.01, 1.58)
1.16 (0.70, 1.90)
1.53 (0.66, 3.56)
3.54 (1.44, 8.70)
1.36 (1.16, 1.60)
6.43 (2.24, 18.43)
4.96 (3.05, 8.06)
2.10 (1.52, 2.91)
100.00
4.20
2.80
1.35
4.81
4.29
6.77
36.89
2.07
Weight
6.49
0.84
5.63
18.85
6.04
4.46
2.43
1.39
6.62
0.87
19.67
3.71
6.17
6.76
4.35
2.36
2.16
7.26
1.70
4.45
%
24.59
1.0543 18.4
Fig. 2 Forest plot of the meta-analysis conducted using a random-effects model to quantify excess mortality in Chagas versus non-Chagas indi-
viduals. (Reference numbers are cited as in the main text)
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proxy for potential improvement in prognosis derived
from the introduction of better treatments over time. The
meta-regression analysis did not find statistical differences
between the two groups regarding this covariate, but this
lack of evidence may be due to the paucity of good quality
studies investigating predictors of mortality in Chagas dis-
ease patients and control groups.
Our study provides a strong evidence base to help in-
form the understanding of Chagas-associated mortality
rates by researchers and practitioners in the field of
Chagas disease. Thus far, although numerous data
sources exist, no consensus on the operation and/or
magnitude of mortality rates due to Chagas disease has
been reached. Some studies looking at the dynamics of
Chagas disease assume an excess mortality for a named
determinate stage (i.e. rates of 0.10) [15], whereas others
simply ignore the excess mortality [42]. A recent review
by Nouvellet et al. [36], exploring different modelling
approaches for Chagas disease, reported a lack of agree-
ment between current models regarding inclusion of
virulence and mortality due to T. cruzi infection, with
mortality rates attributed to Chagas disease ranging be-
tween 0 and 0.30, usually assigned to the final clinical
stage of the disease [43]. Studies assessing the burden
of disease and the cost effectiveness of interventions
[2, 16, 44] have considered excess mortality, with
values ranging from 0.04 to 0.3, depending on
whether heart failure is included. These assumptions
are critically relevant when linking transmission dynam-
ics models and measures of incidence [45] to disease
(morbidity-mortality) models in order to estimate bur-
den of disease, calculate the contribution to DALYs due
to Chagas, and quantify the cost-effectiveness of
interventions. (see [46, 47] for an example of this crucial
process in another NTD).
Our study indicates that much of the heterogeneity in
the mortality rates quoted and used in the literature stems
from a lack of agreement on clearly-defined disease stages.
This results in mortality rates being calculated from
already heterogeneous populations, leading to further con-
fusion between rates of disease progression and mortality.
By classifying Chagas patients using standard clinical
stages used for other heart disease conditions (e.g. the
NYHA classification), we attempted to bring coherence in
the way disease progression and mortality can be defined
and assessed. When evaluating Chagas disease burden, it
will be necessary not only to consider the rates of Chagas-
associated mortality (quantified here) but also the likely
increased probability with which T. cruzi-infected patients
progress from asymptomatic to moderate and to severe
symptoms (e.g. NYHA I–II and NYHA III–IV respect-
ively). While heart conditions typically develop with age,
T. cruzi-infected patients are likely to develop heart dis-
ease earlier in their lives. Therefore, premature death due
to Chagas must account for both the excess mortality in a
particular clinical stage and the increased probability of
progressing to such stage. While this study concerns the
former, further research is needed to address the latter
within a coherent framework to characterise rigorously
rates of clinical progression in Chagas disease.
Finally, a large body of evidence suggests that socioeco-
nomic status also influences the prognosis of cardiovascu-
lar disease [48]. A study investigating socioeconomic
conditions and mortality in Brazil has shown that Chagas
disease acts as a (clinical) predictor alongside socioeco-
nomic situation [49]. However, as Chagas disease is mostly
Fig. 3 Funnel plots of the logarithm of Relative Risk (log(RR)) for Egger’s test of publication bias
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prevalent in poor populations, the independent contribu-
tion of these two factors and their interaction regarding
the risk of mortality may be difficult to disentangle. One
of the studies included in this review [43] found Chagas
disease to be a predictor of all-cause mortality independ-
ently of socio-economic status [49]. Another study [50]
found Chagas disease to be a predictor of mortality due to
stroke after adjusting for educational status among other
variables, with a HR = 2.25 (95 % CI 1.25–4.44), suggesting
that Chagas disease is an independent contributor to
mortality.
Conclusions
The systematic review and meta-analysis conducted in
this study identified a consistent body of evidence indi-
cating that Chagas disease is associated with statistically
significant excess mortality. The relative risk was 1.74
(95 % CI 1.49–2.03) and the attributable risk percent
was 42.5 %. This excess mortality affected all Chagas dis-
ease patients regardless of their clinical presentation.
Annual mortality rates increased with clinical severity.
These results were robust to publication bias and varia-
tions in study quality. Heterogeneity in published mor-
tality rates, and/or lack of recognition of the excess
mortality, is likely to be due to heterogeneity (or ab-
sence) of clinical stage classification. Therefore, we advo-
cate the use of a standardised system of disease severity
such as the NYHA grading system (used here). Adoption
of a well-characterised classification system will also help
in the much needed estimation of rates of disease progres-
sion associated with T. cruzi infection. Our results have
implications for the mathematical modelling, burden of
disease estimation and economic evaluations of American
trypanosomiasis and its control.
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